HOME >> MEDICINE >> NEWS
Conference examines latest research on drug-induced liver injury

A recent conference examined issues relating to drug-induced liver injury (DILI), the primary cause of acute liver failure in the U.S. The proceedings of the conference are summarized in a paper appearing in the March 2006 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Held in Atlanta, GA in September 2005, the conference focused on idiosyncratic DILI, the most problematic form, in which a combination of genetic and non-genetic factors unexpectedly make some patients susceptible to drug injury. There are currently no valid animal models for studying idiosyncratic DILI, and it is difficult to study it in humans since its incidence is relatively rare. The Drug-Induced Liver Injury Network was established in 2003 with the aim of creating a registry of DILI patients and advancing research and treatment methods that could benefit those suffering from DILI. "The Single Topic Conference provided an opportunity for basic, translational and clinical researchers to 'sit at the same table' in discussions about the promise and challenges of DILI research," the authors state.

Discovering the factors involved in idiosyncratic DILI will hopefully lead to the development of clinical tests that can identify those patients susceptible to it so that injury can be avoided. "The identity of these factors should also shed light on underlying mechanisms and thereby allow development of safer drugs," the authors note. Safety issues are a major reason for failure of drugs in clinical trials, and DILI is the most common factor for failure to approve drugs or restrict their use.

There are instances where liver damage caused by certain drugs has been documented. This is the case with acetamino
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Mar-2006


Page: 1 2

Related medicine news :

1. Home health care devices focus of FDA Conference at UH
2. Conference to investigate basis of parental behavior
3. Research highlights from Thoracic Society Conference
4. NYP/Weill Cornell Urologists present at 2007 AUA Conference
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Conference to focus on transfer of knowledge from research to practice in emergency medicine
7. National Autism Conference slated for June
8. Conference honoring UH professor attracts researchers from United States, abroad
9. Conference session highlights importance of interdisciplinary approach to Earth system science
10. Global Environmental Change and Human Health: New project launched at GEC Conference in Beijing
11. Case Western Reserve University hosts 100th Anniversary of Alzheimers Disease Conference

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Conference examines latest research drug induced liver injury

(Date:5/23/2013)... Nashville, TN (PRWEB) May 23, 2013 ... to enhance nurse understanding of the professional role and ... , Roland Joy, vice president of patient care services ... explains, "TAMC nurses are excellent clinicians, and we want ... profession, teach them that to lead they must follow, ...
(Date:5/23/2013)... Portland, Oregon (PRWEB) May 23, 2013 Better ... touches as it prepares to launch its one of ... Final training of management staff will be completed May 29th, ... Chris and Heather Richardson completed on site training in Portland ... the 29th to complete operational training. , "It really is ...
(Date:5/23/2013)... PhD Box has introduced a service ... research process by offering assistance for Thesis Proposals. The proposal ... services that the company provides for research consultation in various ... proposal writing service is that this is the stage where ... process find it difficult to draft a proposal as it ...
(Date:5/23/2013)... Sunnyvale, CA (PRWEB) May 23, 2013 Footwear ... Dansko Vista Collection of sandals containing cork footbeds. ... Dansko has had consistently good sales for many years, and ... this spring and summer. , Dansko Shoes ... and the Vista Collection is no exception. Containing leather and ...
(Date:5/23/2013)... 23, 2013 Following the recent outbreak ... internet users, the security team at idcloak Technologies has ... against this or any web-born malware. Gill-Chris Welles ... provides far better privacy and security than ... that even the best AV software cannot be depended ...
Breaking Medicine News(10 mins):Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2Health News:Footwear etc. Announces the New Collection of Dansko Cork Sandals 2Health News:Effective virus protection without anti-virus software, identifies idcloak 2
(Date:5/22/2013)... , May 22, 2013 Advanced Prenatal ... medical device that will help alleviate the high blood ... apheresis cartridge is expected to be the first medical ... of maternal and fetal death. Every year, ... the United States . It is characterized by ...
(Date:5/22/2013)... 2013 Attorney Advertising -- Bronstein, Gewirtz & ... of purchasers of the securities of AMAG Pharmaceuticals, ... The investigation focuses on whether the Company and ... On May 22, 2013, Shares of AMAG dropped ... company announced in regulatory filing that it has ...
(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...
Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
Cached News: